SCHEMBL2282129

SCHEMBL2282129

c1ccc(C2=NCCN=C2c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 5/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
NR1I2 O75469 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
HTR2C P28335 1/20 0.40
ADRA1A P35348 1/20 0.40
PTGS2 P35354 1/20 0.40
OPRK1 P41145 1/20 0.40
CHRNA4 P43681 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PDE4D Q08499 1/20 0.40
NOTUM Q6P988 1/20 0.39
MAPK10 P53779 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28474885 0.89 CHRNB4 (0.52) NISCHCHRNB4CHRNA3ALDH1A1GAA
SCHEMBL6810811 0.82 ALDH1A1 (0.44) NISCHCHRNB4CHRNA3ALDH1A1GAA
SCHEMBL2274850 0.74 NISCH (0.35) NISCHCHRNB4CHRNA3ALDH1A1GAA
SCHEMBL4151921 0.72 MAPK10 (0.41) RAB9ANPC1PTGS2NOTUMMAPK10
SCHEMBL14525912 0.70 ALDH1A1 (0.46) ALDH1A1GAARAB9ANPC1MAPK1
SCHEMBL9197869 0.70 NISCH (0.40) NISCHCHRNB4CHRNA3ALDH1A1GAA
SCHEMBL895819 0.69 CHRNB4 (0.67) NISCHCHRNB4CHRNA3ALDH1A1GAA
SCHEMBL12997586 0.67 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPK1ADORA3
SCHEMBL1068403 0.67
SCHEMBL576916 0.67 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109384733-B Method for preparing celecoxib intermediate compound in high yield under mild condition 新发药业有限公司 2020-04-28 CN disclosed
CN-109384733-A The method of Sai Lexipa midbody compound is prepared under a kind of temperate condition in high yield 新发药业有限公司 2019-02-26 CN disclosed
US-8084145-B2 Organometallic complex, light emitting element using the complex, light emitting device using the element, and electric apparatus using the device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-12-27 US disclosed
US-8084145-B2 Organometallic complex, light emitting element using the complex, light emitting device using the element, and electric apparatus using the device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-12-27 US disclosed
US-8084145-B2 Organometallic complex, light emitting element using the complex, light emitting device using the element, and electric apparatus using the device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-12-27 US disclosed
US-7993494-B2 Method for manufacturing triarylpyrazine derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-08-09 US disclosed
US-7993494-B2 Method for manufacturing triarylpyrazine derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-08-09 US disclosed
CN-101481357-B Preparation of quinoxaline derivatives UNIV TIANJIN NORMAL 2010-12-08 CN disclosed
US-20090183982-A1 Method for Manufacturing Triarylpyrazine Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-07-23 US disclosed
US-20090183982-A1 Method for Manufacturing Triarylpyrazine Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-07-23 US disclosed
CN-101481357-A Preparation of quinoxaline derivatives UNIV TIANJIN NORMAL (CN) 2009-07-15 CN disclosed
US-7355075-B2 Reacting a compound of a hydroxyl functionality, a carbonyl functionality, or both a hydroxyl functionality and a carbonyl functionality with reactant having an amine functionality in the presence of ordered porous manganese-based octahedral molecular sieves and an oxygen gas THE UNIVERSITY OF CONNECTICUT (US) 2008-04-08 US disclosed
US-7355075-B2 Reacting a compound of a hydroxyl functionality, a carbonyl functionality, or both a hydroxyl functionality and a carbonyl functionality with reactant having an amine functionality in the presence of ordered porous manganese-based octahedral molecular sieves and an oxygen gas THE UNIVERSITY OF CONNECTICUT (US) 2008-04-08 US disclosed
US-20070027344-A1 METHOD OF PRODUCING IMINES THE UNIVERSITY OF CONNECTICUT (US) 2007-02-01 US disclosed
US-20070027344-A1 METHOD OF PRODUCING IMINES THE UNIVERSITY OF CONNECTICUT (US) 2007-02-01 US disclosed
US-20050221123-A1 Organometallic complex, light emitting element using the complex, light emitting device using the element, and electric apparatus using the device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2005-10-06 US disclosed
EP-0397859-A1 PYRAZINE DERIVATIVES AND MEDICINAL PREPARATION CONTAINING SAME TERUMO KABUSHIKI KAISHA (JP) 1990-11-22 EP disclosed
EP-0194686-B1 PYRAZINE DERIVATIVES TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) 1989-12-20 EP disclosed
US-4788197-A ANTICOAGULANTS TERUMO KABUSHIKI KAISHA (JP) 1988-11-29 US disclosed
EP-0194686-A1 Pyrazine derivatives TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027344-A1 METHOD OF PRODUCING IMINES MT-CO2, INMT, SCO2 NISCH 175/4885CHRNB4 3860/4885CHRNA3 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.